Last reviewed · How we verify
Placebo for apixaban
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in apixaban clinical trials (specific indication depends on parent trial).
At a glance
| Generic name | Placebo for apixaban |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug through comparison. In this case, it serves as the control arm in phase 3 trials of apixaban, a Factor Xa inhibitor anticoagulant. Any observed clinical benefit in the placebo group is attributed to natural disease progression, regression to the mean, or the placebo effect.
Approved indications
- Control arm in apixaban clinical trials (specific indication depends on parent trial)
Common side effects
Key clinical trials
- A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (PHASE3)
- REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults (PHASE3)
- Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism (PHASE4)
- Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment (PHASE3)
- Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT (PHASE2)
- Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension (PHASE3)
- Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults (PHASE2)
- COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for apixaban CI brief — competitive landscape report
- Placebo for apixaban updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI